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Drugsforpsychiatricproblemsareprescribedontheassumption
that they mostly act against neurochemical substrates of
disorders or symptoms. In this article we question that
assumption, proposing that drugs’ action be viewed rather as
producing altered, drug induced states, a view we have called
the drug centred model of action. We believe that this view
accords better with the available evidence. It may also allow
patientstoexercisemorecontroloverdecisionsaboutthevalue
of pharmacotherapy, helping to move mental health treatment
in a more collaborative direction.
Assumptions about mode of action
The widespread use of psychiatric drugs is justified by the idea
that they work by correcting, or helping to correct, underlying
biological abnormalities that produce particular psychiatric
symptoms. We have called this view the disease centred model
ofpsychiatricdrugaction(table⇓).Mostdrugsusedinmedicine
can be understood as working according to a disease centred
model—even analgesics, for example, work by acting on the
physiological mechanisms that produce pain. In psychiatry, the
disease centred model is reflected in the names of the major
drugclasses:antidepressantsarebelievedtoreversebiochemical
pathways that give rise to symptoms of depression and
antipsychotics are thought to act on mechanisms that produce
psychotic symptoms. From this viewpoint, the therapeutic
actions of drugs (their actions on disease processes) can be
distinguishedfromothereffects,accordinglytermedsideeffects.
An alternative, drug centred model of drug action, stresses that
psychiatric drugs are, first and foremost, psychoactive drugs.
They induce complex, varied, often unpredictable physical and
mental states that patients typically experience as global, rather
thandistincttherapeuticeffectsandsideeffects(table⇓).Drugs
may be useful because some altered states can suppress the
manifestations of certain mental disorders.
Thediseasecentredmodelofdrugactiondevelopedinthe1950s
and 1960s and replaced a drug centred understanding of how
psychiatric drugs worked.
1 For example, the early investigators
ofneurolepticorantipsychoticdrugssuggestedthattheyworked
by inducing a neurological syndrome consisting of physical
restriction and mental symptoms such as cognitive slowing,
apathy, and emotional flattening, which resembled Parkinson’s
disease.
2 These effects also reduced the intensity of psychotic
symptoms. Thus, extrapyramidal effects, and their conjoined
mental effects, were not regarded as side effects but as the
mechanism by which the drugs produced their intended
outcome.
3
Inducingovertparkinsonismhaslongbeenthoughtunnecessary
to produce a therapeutic effect, yet there has been little
considerationofthementalalterationsproducedbyneuroleptic
drugs and just how these might interact with psychotic
symptoms. Some modern commentators have suggested that
theemotionalindifferenceinducedbyneurolepticsaccountsfor
their therapeutic effects,
4 and empirical research supports this
position.
5 Overall, the drug centred model suggests looking
more closely at how psychological alterations produced by
psychiatric drugs interact with the experiences of distress and
psychosocial disability that lead people to seek clinical help.
6
Evidence on psychiatric drug action
Both models help clarify possible mechanisms of drug action
and need not be mutually exclusive. However, the neglect of
thepsychoactiveeffectsofpsychiatricdrugshasmadeitdifficult
to establish disease specific actions. For example, placebo
controlledtrialsarenotdesignedtodistinguishwhetherobserved
outcomes occur because of the drug’s action on an underlying
pathological process or as a consequence of being in an altered
state. Psychoactive effects, including sedation, psychomotor
slowing, activation, and altered sense perception, could have
aneffectonthesymptomsofdistressincountlessdisordersand
be distinguished from effects associated with inert placebo.
6
Any drug with sedative properties, for example, will modify
disturbances of sleep and arousal found in many psychiatric
conditions and in the disorder specific rating scales used in
clinical trials.
A second difficulty has been a paucity of realistic trials that use
activeplacebosorcomparedrugsbelievedtobedisorderspecific
(accordingtocurrentdiagnosticclassificationsortheories)with
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trials comparing chlorpromazine and barbiturates favoured
chlorpromazine, but comparisons with benzodiazepines give
mixed results,
7 and a trial using opium as a comparator found
no difference.
8 However, although evidence of the superiority
of antipsychotics might imply disease specific effects, superior
effects can also be explained within a drug centred framework.
This view suggests that the characteristic psychomotor and
emotionalrestrictioninducedbyantipsychoticsismoreeffective
at suppressing psychotic agitation than other sedatives, as
proposed by the early investigators.
2
Drugs not normally considered to be antidepressants, including
antipsychotics, benzodiazepines, and stimulants, have been
found to have comparable effects to antidepressants in people
with depression.
9 Comparisons of lithium with antipsychotics
and benzodiazepines have not confirmed its superiority to treat
mania or affective psychosis.
10 Although one study suggested
some differential effect on particular symptoms,
11 others have
not.
12
Biochemical aetiological theories such as the dopamine theory
of schizophrenia or psychosis and the monoamine hypothesis
of depression seem to support a disease centred view of drug
action, although their strongest support remains the presumed
specificity of drug treatment. Proponents of the dopamine
hypothesis argue that antipsychotics exert their therapeutic
action by correcting an underlying dopamine dysregulation.
13
However, little evidence suggests that any abnormality of the
dopamine system is specific to psychosis and not accounted for
by other factors associated with dopamine activity, such as
increased arousal or stress. That some effective antipsychotic
drugs such as clozapine have relatively weak actions on
dopamine receptors also seems to contradict the theory.
14
Evidence for the monoamine hypothesis, which states that
antidepressantsworkbycounteringadeficiencyofnoradrenaline
or serotonin activity, is also questionable. Many different
investigations of the drugs’ metabolites and receptors in
depressedpeopleandpostmortemexaminationshaveproduced
no reliable demonstration of such a deficiency.
15
Generally, there have been few attempts to evaluate the
dominant, disease centred explanation for drug action in
psychiatry because few people realise that an alternative
explanation exists.
1 The little available evidence does not yet
providecompellinggroundstoacceptthediseasecentredmodel.
Drug centred model in research
There has been little systematic exploration of the full range of
psychoactiveandphysicaleffectsproducedbypsychiatricdrugs.
This information is typically obscured by short clinical trials
that focus on narrow complaints and outcomes and relegate
othereffectstothestatusofsideeffects.
16Thereisalsoapaucity
of research on the often unpredictable, long term effects of
drugs, the consequences of drug withdrawal, and the nature of
the large black box presently called the placebo effect.
Forexample,thenatureofthesubjectivestateinducedbytaking
selective serotonin reuptake inhibitors (SSRIs), and how it
interacts with expectancy effects, remains unclear. Volunteer
studies suggest these drugs may have concurrent sedative and
activating or stimulant effects,
17 and some research indicates
they reduce emotional responsiveness, but this has not been
confirmed.
18Howtheycausesuicidalideation,iftheydo,isalso
not established. Similarly, few data exist about the subjective
effectsproducedbysecondgenerationantipsychotics,howthey
differfromeachother,andwhethertheyaresimilartotheeffects
produced by older antipsychotics. Obviously, this information
is crucial if people are to make informed choices about whether
these drugs are likely to improve their mental state and what
price might be paid in return.
Morecomprehensivevolunteerstudiesareneededtoobtaindata
on the full range of effects of psychiatric drugs. It is also
important to pay attention to patients’ uncensored accounts of
taking psychiatric drugs, available on the internet, for example.
Clinical trials need to devise ways to explore patients’
experiences more directly than through clinicians’ diagnoses
and symptom rating scales. Patients’ views also need to be
collected after the drugs have been stopped, since many effects
may be difficult to identify while in a drug induced state.
Implications for clinical practice
Messages conveyed in information leaflets and advertising
campaigns have persuaded millions of people that mental
disordersarecausedbychemicalimbalancesthatcanberectified
by drugs.
19 However, given the paucity of the evidence, we
suggest that prescribers should not present the drugs they
prescribe for mental disorders as disease specific treatments.
Psychiatricdrugsmightneedrenaming,toavoidthepresumption
of specificity built into labels like antidepressants and
antipsychotics.
The drug centred model may change attitudes to psychiatric
drugs and empower patients to be more involved in decisions
abouttreatment.Whereasadiseasecentredmodelhasabuilt-in
assumption that drug treatment is likely to be physiologically
corrective and therefore beneficial, a drug centred model, by
stressing that drugs are extrinsic substances that alter how the
body works, demands that the advantages and disadvantages of
taking a drug be carefully weighed up and distinguished from
theeffectsoftreatmentingeneral.Highlightingthatpsychiatric
drugs are psychoactive substances allows people to judge for
themselves what sort of drug induced effects might help them
and what sort might not. Patients become the ultimate arbiters
of the value of taking a particular drug and are encouraged to
takeanactiveroleinadjustingdrugregimenstosuittheirneeds.
In the short term, for example, the cognitive and emotional
suppression described by people who have taken antipsychotic
drugs may bring relief to someone traumatised by intense
psychotic experiences and allow people to engage better with
theworldaroundthem.
20However,afterrecoveryfromanacute
episode, some people may decide that the costs of continued
drug treatment are not outweighed by the reduction in the risk
of relapse that long term treatment may produce. According to
a drug centred model, therefore, non- compliance may be a
rationalresponsetotheeffectsofdrugs,whichprescribersneed
to understand and accommodate rather than overcome.
People with depression are likely to respond differently to an
offer of a drug intended to produce an altered state than a drug
saidtoactontheunderlyingbiologicalmechanismofdepressive
symptoms. Various psychoactive drugs, such as antipsychotics
andpossiblySSRIs,maysuppresstheexperienceorexpression
of emotions, including feelings of depression, but it seems
unlikely that many people would desire this kind of effect. On
the other hand, some people with depression may find drugs
with sedative effects, such as benzodiazepines and low dose
tricyclicantidepressants,usefultemporarilytobringrelieffrom
troubled sleep, anxiety, and agitation.
In this way, the drug centred model provides a rationale for
periodic rather than continuous drug use, to cope with
exacerbationsofsymptomsortopalliatestressfulenvironmental
events and avoid the harm associated with long term use. It
questions the use of complex drug cocktails, commonly
For personal use only: See rights and reprints http://www.bmj.com/permissions Subscribe: http://www.bmj.com/subscribe
BMJ 2009;338:b1963 doi: 10.1136/bmj.b1963 (Published 29 May 2009) Page 2 of 4
ANALYSISprescribed in the United States, for example, based on the
presumed fit between different drugs and multiple diagnoses
given to a patient. It also allows doctors, patients, and people
who know patients to properly monitor the full consequences
ofdrugtreatmentandengageinanongoingdialogueabouthow
it compares with alternative interventions.
Medicine, as a whole, has started to recognise the importance
of involving patients in decisions about their care. By
highlighting the nature of psychiatric drugs as psychoactive
substances that produce altered states, the drug centred model
may enable patients to participate more equally in the process
ofevaluatingthelikelyeffectofdrugtreatmentintheirparticular
situation. A drug centred model also imposes a duty on the
psychiatric research community to produce relevant, unbiased
information about the range of effects that psychiatric drugs
exert on thought, emotion, and all bodily systems, both during
short term and long term use. At present, the influence of the
disease centred model keeps the full range of effects of many
drugsobscured,andhenceneitherdoctorsnorpatientscanmake
properlyinformeddecisionsabouttherisksandbenefitsofusing
them.
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Table 1| Models of psychiatric drug action
Drug centred model Disease centred model
Drugs create an altered physical and mental state Drugs correct an abnormal brain state
Therapeutic effects are a consequence of being in an altered state Therapeutic effects arise from the action of drugs on an underlying disease process
Indication is the value of particular drug induced effects Main indication is the presence of a particular disease
For personal use only: See rights and reprints http://www.bmj.com/permissions Subscribe: http://www.bmj.com/subscribe
BMJ 2009;338:b1963 doi: 10.1136/bmj.b1963 (Published 29 May 2009) Page 4 of 4
ANALYSIS